Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
217 hedge funds and large institutions have $5.02B invested in Mirati Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 58 increasing their positions, 69 reducing their positions, and 62 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 9 → 18 (+9)
42% more capital invested
Capital invested by funds: $3.53B → $5.02B (+$1.49B)
2% more funds holding
Funds holding: 213 → 217 (+4)
10% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 62
15% less call options, than puts
Call options by funds: $87.7M | Put options by funds: $103M
16% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$555M |
| 2 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$176M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$152M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$106M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$92.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$145M |
| 2 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$137M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$135M |
| 4 |
AG
Artal Group
Luxembourg
|
-$114M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$100M |
MRTX Hedge Fund Activity: Q4 2023 in Review
217 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2023, worth a combined $5.02B — up 42% from $3.53B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new MRTX positions and 62 closed out — a net gain of 6 holders — while 58 added to existing stakes and 69 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $555M. The largest seller was Wellington Management Group, exiting entirely with an estimated $145M sold.
- 217 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2023, up from 213 in Q3 2023.
- Funds reported $5.02B of Mirati Therapeutics, Inc. Common Stock stock for Q4 2023, up 42% quarter-over-quarter.
- 68 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2023 and 62 closed out, a net change of +6 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2023 was Morgan Stanley, an estimated $555M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2023 was Wellington Management Group, an estimated $145M sold.
Based on aggregated 13F filings for Q4 2023.